SCHEMBL2570865

SCHEMBL2570865

COC(=O)CCC1=CCCNC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
TSHR P16473 2/20 0.36
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
EGFR P00533 3/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
CHRM3 P20309 1/20 0.35
KAT2B Q92831 1/20 0.33
SRC P12931 1/20 0.33
DYRK1A Q13627 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2564339 0.84 PDE3B (0.40) PDE3BPDE3ATSHRALDH1A1HSD17B10
SCHEMBL11698888 0.76 GSTP1 (0.40) PDE3BPDE3ATSHRALDH1A1HSD17B10
SCHEMBL2566986 0.71 HDAC3 (0.45) KAT2BHDAC3HDAC4HDAC1HDAC7
SCHEMBL2567966 0.67 TSHR (0.38) TSHRALDH1A1HSD17B10KDM4ELMNA
SCHEMBL11764316 0.67 TSHR (0.44) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL19245968 0.66
SCHEMBL25049307 0.66 PDE3B (0.40) PDE3BPDE3ATSHRALDH1A1HSD17B10
SCHEMBL13056322 0.66 TSHR (0.36) PDE3BPDE3ATSHRALDH1A1HSD17B10
SCHEMBL11762132 0.66 TSHR (0.42) PDE3BPDE3ATSHRALDH1A1HSD17B10
SCHEMBL11701038 0.65 HPGD (0.43) PDE3BPDE3ATSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1626961-B1 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RES INST OF BIOSCIENCE (KR) 2011-11-02 EP disclosed
US-7846963-B2 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2010-12-07 US disclosed
US-20100286207-A1 Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2010-11-11 US disclosed
US-7723376-B2 2-oxo-heterocyclic compounds and pharmaceutical compositions KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2010-05-25 US disclosed
EP-1626961-A4 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RES INST OF BIOSCIENCE (KR) 2008-07-16 EP disclosed
US-20070167486-A1 Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-19 US disclosed
US-20060173043-A1 Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2006-08-03 US disclosed
EP-1663201-A1 A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2006-06-07 EP disclosed
EP-1626961-A1 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2006-02-22 EP disclosed
WO-2005004861-A1 A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-01-20 WO disclosed
WO-2004101523-A1 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286207-A1 Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same NOD2, BMP2, NOD1 PDE3B 121/4885PDE3A 151/4885TSHR 3661/4885
US-20070167486-A1 Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same NOD2, NOD1, BMP2 PDE3B 176/4885PDE3A 199/4885TSHR 3569/4885
US-20060173043-A1 Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same MALT1, BRCA1, MCL1 PDE3B 165/4885PDE3A 407/4885TSHR 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.